Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
669-01-010 ISMRM Abstract

Longitudinal 7T MR Spectroscopic Imaging of Early Relapsing-Remitting Multiple Sclerosis Before and After Therapy Initiation

Primary: Contrast Mechanisms - Spectroscopy
Secondary: Neuro - Multiple Sclerosis
669-01-010 · Neuroinflammation: Metabolites, Function, and AI · Thursday, 14 May, 8:30 AM–9:25 AM · Digital Posters Row J
Keywords: Treatment Response Multiple Sclerosis MRSI Normal Appearing White Matter Metabolic marker
Accepted
Anna Zöchner 1,2, Wolfgang Bogner1,2,3, Assunta Dal-Bianco4,5, Bernhard Strasser1, Lukas Hingerl1, Rebeka Rumbak1, Paulus Rommer4, Eva Niess1
1High Field MR Center, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
2Christian Doppler Laboratory for MR Imaging Biomarkers (BIOMAK), Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
3Comprehensive Center for Artificial Intelligence in Medicine, Medical University of Vienna, Vienna, Austria
4Department of Neurology, Medical University of Vienna, Vienna, Austria
5Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria
Presenting Author: Anna Zöchner

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 Apr 6;359(9313):1221-31. doi: 10.1016/S0140-6736(02)08220-X. Erratum in: Lancet 2002 Aug 24;360(9333):648. PMID: 11955556. [doi] [pmid]
2. Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011 Dec;68(12):1514-20. doi: 10.1001/archneurol.2011.914. PMID: 22159052. [doi] [pmid]
3. Tzanetakos D, Kyrozis A, Karavasilis E, Velonakis G, Tzartos JS, Toulas P, Sotirli SA, Evdokimidis I, Tsivgoulis G, Potagas C, Kilidireas C, Andreadou E. Early metabolic alterations in the normal‑appearing grey and white matter of patients with clinically isolated syndrome suggestive of multiple sclerosis: A proton MR spectroscopic study. Exp Ther Med. 2023 May 30;26(1):349. doi: 10.3892/etm.2023.12048. PMID: 37324507; PMCID: PMC10265702. [doi] [pmid]
4. Hingerl L, Strasser B, Moser P, Hangel G, Motyka S, Heckova E, Gruber S, Trattnig S, Bogner W. Clinical High-Resolution 3D-MR Spectroscopic Imaging of the Human Brain at 7 T. Invest Radiol. 2020 Apr;55(4):239-248. doi: 10.1097/RLI.0000000000000626. PMID: 31855587. [doi] [pmid]
5. Bellmann-Strobl J, Stiepani H, Wuerfel J, Bohner G, Paul F, Warmuth C, Aktas O, Wandinger KP, Zipp F, Klingebiel R. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol. 2009 Aug;19(8):2066-74. doi: 10.1007/s00330-009-1364-z. Epub 2009 Mar 24. PMID: 19308417. [doi] [pmid]
6. Yetkin MF, Mirza M, Dönmez H. Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis. Medicine (Baltimore). 2016 Sep;95(36):e4782. doi: 10.1097/MD.0000000000004782. PMID: 27603381; PMCID: PMC5023904. [doi] [pmid]
7. Mueller C, Baird JF, Motl RW. Whole-Brain Metabolic Abnormalities Are Associated With Mobility in Older Adults With Multiple Sclerosis. Neurorehabil Neural Repair. 2022 Apr;36(4-5):286-297. doi: 10.1177/15459683221076461. Epub 2022 Feb 14. PMID: 35164595; PMCID: PMC9007860. [doi] [pmid]
8. Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol. 2014 Jul 1;71(7):840-7. doi: 10.1001/jamaneurol.2014.895. PMID: 24839987. [doi] [pmid]
9. Heckova E, Dal-Bianco A, Strasser B, Hangel GJ, Lipka A, Motyka S, Hingerl L, Rommer PS, Berger T, Hnilicová P, Kantorová E, Leutmezer F, Kurča E, Gruber S, Trattnig S, Bogner W. Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. Radiology. 2022 Apr;303(1):141-150. doi: 10.1148/radiol.210614. Epub 2022 Jan 4. PMID: 34981978. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/669-01-010